… 2021, 9 a.m. GMT/10 a.m. CDT/11 a.m. EDT) --Pre-treatment circulating tumor (ct)DNA levels more accurately predicted long-term survival than …

… PD-L1 inhibition overcomes T-cell suppression at the tumor; and chemotherapy causes tumor cell death and antigen … molecularly characterized via sequencing of tumor tissue DNA and/or circulating tumor DNA samples. Progression free survival and …

… Barcelona— Tumor mutational burden was not significantly associated … Garassino from theFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Dr. Garassino presented this new data … by whole-exome sequencing of tumor and matched normal DNA. The clinical utility of TMB on outcomes was assessed …

… reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based … and pemetrexed or carboplatin and pemetrexed alone. Tumor mutational burden was determined by whole exome sequencing of tumor and matched normal DNA. Langer and the KEYNOTE 021 researchers were able to …

… laboratory projects focus on the clonal evolution of tumors, cell-free plasma DNA as biomarkers for early detection, and the role of …

… biology and its evolution over time, using tools like circulating tumour DNA from liquid biopsies, to match patients to the adjuvant … a targeted therapy,” she stated. “The possibility to study circulating tumour cells from blood samples has been a …

… Award to Gabriella Sozzi, PhD. Dr. Sozzi leads the Tumor Genomics Unit at Fondazione IRCCS Istituto Nazionale Tumori (INT) in Milan, Italy. She graduated in Biological … of lung cancer in screening programs. In the field of circulating biomarkers, she has a demonstrated record of …